RU145507U1 - DOUBLE BLOOD REMOVING PACKAGE - Google Patents

Abstract

A double hemostatic package containing a hemostatic agent, characterized in that the package is divided into two parts, the first containing an ampoule with 10 ml of a solution of 36% polycresulenic acid in a 1: 1 dilution of 0.9% saline, surrounded by an internal multilayer gauze package, and in the second, separated from the first part, a bandage is included.

Description

The utility model relates to the field of medicine, in particular surgery, field surgery, resuscitation, disaster medicine and allows you to stop bleeding from wounds (except for eye wounds and the ear canal).

A known method of stopping external bleeding using the drug "Hemostop". The drug is a derivative of the mineral (zeolite) NaCaAX, which has a high absorption capacity. A quick stop of bleeding by Hemostop is due to the intensive absorption of water by zeolite. When it comes into contact with blood, a large amount of water is absorbed locally, exceeding the mass and volume of the drug, which leads to an increased local concentration of cellular and large protein components of the blood (including coagulation factors). As a result, the accelerated formation of a blood clot occurs.

In addition, the surface potential of the zeolite NaCaAX favors the activation of the XII coagulation factor and platelets. Calcium contained in the preparation Hemostop is, among other things, a cofactor in many parts of the coagulation process (Instructions for the preparation Manufacturer of the drug: Federal State Unitary Enterprise SPC Pharmzashchita FMBA of the Russian Federation // New technologies in military field surgery and peacetime surgery. Materials of international conference. 2006, p. 169 //, as well as RF patent No. 2436527, A61B 17/00, A61K 33/06, A61P 7/04, published on December 20, 2011).

The disadvantage of this method is:

- “Hemostop” is not subject to open storage and reuse. When depressurizing a vacuum package, the product is not suitable for use, not only because of the possibility of wound contamination, but also because of the rapid moisture saturation of the zeolite. Re-sterilizing the powder is not possible.

- after filling the wound cavity with zeolite, a cotton-gauze swab or a bandage folded in several layers is applied over the powder (to prevent burn injury caused by heat released during the absorption of water - an exothermic reaction), and perform manual compression for 5-7 minutes.

- if hemostasis is not achieved, repeated compression is possible within 3-5 minutes, if after that the bleeding does not stop, it is necessary to apply a hemostatic tourniquet.

- the warranty period of storage of the Hemostop preparation is three years

The utility model is based on the task of creating a double hemostatic package that provides a quick stop of bleeding from wounds.

The solution to the technical problem is ensured by the fact that in a double hemostatic package containing the hemostatic agent “Vagotil (36% polycresulenic acid)” in a 1: 1 dilution with 0.9% saline, the package is divided into two parts, the ampoule with the indicated included in the first a solution in an amount of 10 ml, surrounded by an internal multilayer gauze package, and a bandage is included in the second, separated from the first part by a notch.

The utility model is illustrated using figures 1-3, which shows the technique of using a hemostatic package to stop bleeding from a wound, shown in figure 1.

The utility model “double styptic package” works as follows: the wounded can be in any conditions. Anesthesia is not required. After performing a digital pressing of the artery to the osseous protrusion, the “double hemostatic package” strikes the hard surface with one hand (or kneads by compression with a brush, or attacks the “hemostatic package”), trying to direct the main efforts to half the package painted in Red color. At the same time, the ampoule containing “Vagotil (36% polycresulenic acid)” in a 1: 1 dilution of 0.9% saline solution contained therein breaks up and the liquid moistens the internal multilayer gauze package. Glass fragments do not go outside the inner gauze package. The outer red plastic sheath is completely torn along the existing incision No. 1 and moistened with “Vagotil (36% polycresulenic acid)” in a 1: 1 dilution with 0.9% saline, the multilayer gauze package is shaken out into the wound (see FIG. 2). The resulting reaction causes a coagulating effect. A deep burn of the surrounding tissue does not occur (see figure 3). The spilled blood coagulates and turns gray. On the notch No. 2, the second part of the “double hemostatic package” is torn, from where the bandage for the dressing is obtained.

It should be ensured that the excess solution of polycresulenic acid should not get into the eyes and the ear canal.

Using this method of stopping bleeding can prevent blood loss. It is from her that in most cases an unfavorable outcome occurs. The time to stop bleeding is 15-20 seconds.

Other available methods and devices either have contraindications, or are expensive and require special equipment, or are technically difficult to perform.

Claims (1)

A double hemostatic package containing a hemostatic agent, characterized in that the package is divided into two parts, the first containing an ampoule with 10 ml of a solution of 36% polycresulenic acid in a 1: 1 dilution of 0.9% saline, surrounded by an internal multilayer gauze package, and in the second, separated from the first part, a bandage is included.